NAD+ vs NMN vs NR — What the Research Actually Shows, and What UAE Researchers Should Buy

NAD+, NMN, and NR aren't three competing molecules — they're three points along a single biosynthetic pathway. Pick the wrong one for your delivery route and you've wasted both peptide and time. This research-grade comparison walks the salvage pathway, the published bioavailability data, and the practical decision for UAE peptide researchers ordering NAD+ via REVIVE LAB.

1. The salvage pathway in one diagram

NAD+ in mammalian cells comes from three converging routes: de novo synthesis from tryptophan, the Preiss-Handler pathway from niacin, and the salvage pathway from nicotinamide. The salvage route is the dominant one in adult mammalian tissue and is the route that NMN and NR feed into.

• NR (nicotinamide riboside) → enters cell via equilibrative nucleoside transporters → phosphorylated to NMN by NRK1/NRK2
• NMN (nicotinamide mononucleotide) → adenylated by NMNAT1/2/3 to NAD+
• NAD+ → used by sirtuins (SIRT1-7), PARPs, CD38, and NAD-dependent dehydrogenases

The pathway is bidirectional at every step. Dosing NR raises intracellular NAD+ within ~2-4 hours (Trammell 2016). Dosing NMN does the same on a slightly shorter timeline. Injecting NAD+ raises plasma NAD+ within minutes but is partially dephosphorylated to NMN at the cell membrane before re-entering the cell.

2. NR — the cleanest pharmacokinetic record

Nicotinamide riboside has the largest body of human pharmacokinetic data of the three. Trammell et al. 2016 in Nature Communications showed single oral doses of 100, 300, and 1000 mg in healthy adults raised whole-blood NAD+ measurably, peaking around 8 hours post-dose, with the 1000 mg dose producing roughly a 60% increase.

NR is orally stable, doesn't require enteric coating, and the safety profile across published trials is benign at doses up to 2 g/day. The catch: NR is a small-molecule compound, not a peptide, and is not part of the standard injection-research toolkit. It belongs to the oral-supplement category.

3. NMN — the contested middle step

Nicotinamide mononucleotide is one phosphorylation step above NR. Mills et al. 2016 in Cell Metabolism showed long-term NMN administration mitigated age-associated physiological decline in mice. Yoshino et al.

The mechanistic question that's never been fully resolved is whether NMN crosses the cell membrane intact. Grozio et al. 2019 proposed the Slc12a8 transporter as a dedicated NMN importer in mouse small intestine — that finding has been disputed by other groups (Schmidt 2019), and current consensus models treat NMN as being dephosphorylated to NR at the membrane, transported by ENT1/ENT2, then re-phosphorylated inside the cell. Either way, NMN works orally. Whether it works better than NR per molar dose remains debated.

4. NAD+ — the injected coenzyme

Direct NAD+ administration is the route most relevant to peptide research workflows. The published research has substantially fewer randomised trials than the NR/NMN oral literature, but the pharmacokinetics are straightforward — IV infusion produces immediate plasma NAD+ elevation that drops with a half-life on the order of minutes to hours as the molecule is metabolised.

The standard research-protocol dose for SC NAD+ in the published case literature is 50-100 mg per session, 2-7 days per week, in cycles of 2-4 weeks. The detailed dose-route protocol comparison sits in our NAD+ injection vs IV research writeup.

5. Head-to-head — bioavailability and tissue uptake

The honest take: for chronic background elevation of intracellular NAD+, oral NR has the cleanest published evidence. For acute, route-controlled, bolus delivery — the workflow most peptide researchers are running — injected NAD+ is the standard. NMN sits in between and is the choice most often made by researchers wanting oral dosing with a slightly more direct pathway entry.

6. Why injected NAD+ wins for peptide-research protocols

Adding NAD+ to that stack costs zero additional infrastructure. Adding oral NMN/NR means a separate procurement chain, separate dose-response interpretation, and a different pharmacokinetic profile that doesn't synchronise with the injection schedule of other peptides in the stack.

For researchers building longevity stacks or cognitive stacks with MOTS-c and Semax, NAD+ injection slots cleanly into the same morning or evening dosing block as the other peptides.

8. UAE supply context

NAD+ is one of the fastest-moving SKUs in the UAE peptide market because the longevity-clinic sector in Dubai prices IV NAD+ sessions at AED 1,500-3,500. The question is purity — counterfeit and underdosed NAD+ vials are common in grey-market regional supply.

REVIVE LAB UAE supplies HPLC-verified NAD+ with a per-lot certificate of analysis. NAD+ UAE ships same-day on Dubai orders before 4 PM, 24 hours nationwide, with cold-pack insulation year-round.

9. The summary

• NR has the cleanest oral pharmacokinetic record; for oral protocols, it's the published default.
• NMN works orally but the transporter biology is contested; per molar dose, the advantage over NR isn't established.
• Injected NAD+ delivers a quantifiable bolus, slots into existing peptide-research infrastructure, and has decades of clinical case-series support.
• For UAE peptide researchers running injection-based stacks, NAD+ is the format that fits the workflow.
• REVIVE LAB UAE stocks HPLC-verified NAD+ in 100 mg vials with lot-level COA.